SCHEMBL5158142

SCHEMBL5158142

CC(C)OC(=O)CC(=O)c1cnc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.52
CFTR P13569 1/20 0.49
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDR P35968 1/20 0.46
HPGDS O60760 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
MITF O75030 1/20 0.45
XBP1 P17861 1/20 0.45
PAX8 Q06710 1/20 0.45
KLF5 Q13887 1/20 0.45
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160062 0.86 MGAM (0.58) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL5158122 0.83 MGAM (0.54) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL9944380 0.82 NPC1 (0.60) MGAMCFTRKDM4EKMT2AKDR
SCHEMBL5158352 0.82 MGAM (0.52) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL9700485 0.80 MGAM (0.61) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL5363975 0.79 MGAM (0.68) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL5161544 0.78 MGAM (0.58) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL7100632 0.77 MGAM (0.61) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL8270577 0.77 MGAM (0.65) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL5163220 0.77 MGAM (0.56) MGAMCFTRKDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO MGAM 323/4885CFTR 4725/4885KDM4E 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.